Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
5.250
+0.370 (+7.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
April 12, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
April 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
April 10, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
April 03, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200
March 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
March 01, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
February 27, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
February 23, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
January 27, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
January 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
January 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.